
Abbott Laboratories
ABTNYSEHealthcareMedical - Devices
Previous close
$116.64
+$2.50 · +2.19%
ABT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
83
Deep Value
Momentum
38
Weakening
Sentiment
72
Bullish
Risk resilience
69
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAbbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Robert Ford
- Listed since
- Mar 17, 1980
- Employees
- 115,000
Market position
Day range
Current $116.64
52-week range
Current $116.64
- Open
- $114.02
- Previous close
- $114.14
- Volume
- 9.83M
- 0.79× average
- Average volume
- 12.45M
- Average daily volume
- Market cap
- 201.83B USD
- Beta
- 0.58
- Market reference 1
- 50-day average
- $99.9394
- +16.71% above average
- 200-day average
- $107.08
- +8.93% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 225.43B USD
- P/E (TTM)
- 37.5×
- P/B (TTM)
- 3.98×
- P/S (TTM)
- 4.33×
- EV / EBITDA
- 19.51×
- Earnings yield
- 2.98%
- Free cash flow yield
- 3.38%
- Dividend yield
- 2.13%
Profitability & efficiency
- Gross margin
- 56.80%
- Operating margin
- 17.03%
- Net margin
- 11.65%
- Return on equity
- 12.51%
- Return on assets
- 7.52%
- Return on invested capital
- 8.43%
Financial health
- Debt / equity
- 0.64×
- Current ratio
- 1.58×
- Altman Z-score
- 3.49
- Piotroski F-score
- 5 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44.33B USD | 41.95B USD | 40.11B USD | 43.65B USD | 43.08B USD |
| Cost of goods sold | 19.72B USD | 20.63B USD | 20.07B USD | 21.33B USD | 19.86B USD |
| Gross profit | 24.61B USD | 21.33B USD | 20.04B USD | 22.32B USD | 23.21B USD |
| Research and development | 2.96B USD | 2.82B USD | 2.72B USD | 2.85B USD | 2.74B USD |
| Selling, general, and administrative | 12.38B USD | 11.65B USD | 10.88B USD | 11.11B USD | 11.28B USD |
| Operating expenses | 16.59B USD | 14.47B USD | 13.6B USD | 13.96B USD | 14.01B USD |
| Interest income | 230M USD | 344M USD | 385M USD | 183M USD | 43M USD |
| Interest expense | 341M USD | 603M USD | 698M USD | 315M USD | 410M USD |
| Depreciation and amortization | 2.75B USD | 3.22B USD | 3.24B USD | 3.27B USD | 3.54B USD |
| Operating income | 8.05B USD | 6.83B USD | 6.44B USD | 8.36B USD | 9.2B USD |
| Net income | 6.52B USD | 13.4B USD | 5.72B USD | 6.93B USD | 7.07B USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 0 misses, 5 met estimates
- Average EPS surprise
- +1.11%
- 11 comparable reports
- Latest EPS result
- 1.31
- Estimate 1.28 · Beat by 2.34%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$123.64
6.00% upsideRating distribution
41 ratingsRecent analyst actions
ABT news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$2.36
2025 complete year+31.1% since 2021
2026 partial: $1.89
$1.80
2,021
$1.88
2,022
$2.04
2,023
$2.20
2,024
$2.36
2,025
$1.89
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 15, 2026 | $0.63Quarterly | Jul 15, 2026 | Aug 17, 2026 |
Dividend | Apr 15, 2026 | $0.63Quarterly | Apr 15, 2026 | May 15, 2026 |
Dividend | Jan 15, 2026 | $0.63Quarterly | Jan 15, 2026 | Feb 13, 2026 |
Dividend | Oct 15, 2025 | $0.59Quarterly | Oct 15, 2025 | Nov 17, 2025 |
Dividend | Jul 15, 2025 | $0.59Quarterly | Jul 15, 2025 | Aug 15, 2025 |
Dividend | Apr 15, 2025 | $0.59Quarterly | Apr 15, 2025 | May 15, 2025 |
Ex-dividend Jul 15, 2026
$0.63
Quarterly
Record Jul 15, 2026 · Payment Aug 17, 2026
Ex-dividend Apr 15, 2026
$0.63
Quarterly
Record Apr 15, 2026 · Payment May 15, 2026
Ex-dividend Jan 15, 2026
$0.63
Quarterly
Record Jan 15, 2026 · Payment Feb 13, 2026
Ex-dividend Oct 15, 2025
$0.59
Quarterly
Record Oct 15, 2025 · Payment Nov 17, 2025
Ex-dividend Jul 15, 2025
$0.59
Quarterly
Record Jul 15, 2025 · Payment Aug 15, 2025
Ex-dividend Apr 15, 2025
$0.59
Quarterly
Record Apr 15, 2025 · Payment May 15, 2025
ABT peers
ETFs holding ABT
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.86B0.25%2.3T USD0.03%$378.24+0.44%
Schwab U.S. Dividend Equity ETFSCHD5.44B4.86%112B USD0.06%$35.11+0.80%
Vanguard S&P 500 ETFVOO4.83B0.29%1.7T USD0.03%$703.71+0.39%
iShares Core S&P 500 ETFIVV2.68B0.30%891.84B USD0.03%$769.31+0.39%
State Street SPDR S&P 500 ETFSPY2.47B0.30%817.87B USD0.09%$765.72+0.41%
Vanguard Morningstar Value ETFVTV1.75B0.68%256.5B USD0.03%$226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV1.43B3.20%44.76B USD0.08%$174.62+1.29%
Vanguard Dividend Appreciation ETFVIG1.04B0.79%130.9B USD0.04%$243.91+0.69%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 5.86B
- Weight
- 0.25%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Schwab U.S. Dividend Equity ETFSCHD- Market value
- 5.44B
- Weight
- 4.86%
- AUM
- 112B USD
- Expense ratio
- 0.06%
- Price / 1D
- $35.11+0.80%
Vanguard S&P 500 ETFVOO- Market value
- 4.83B
- Weight
- 0.29%
- AUM
- 1.7T USD
- Expense ratio
- 0.03%
- Price / 1D
- $703.71+0.39%
iShares Core S&P 500 ETFIVV- Market value
- 2.68B
- Weight
- 0.30%
- AUM
- 891.84B USD
- Expense ratio
- 0.03%
- Price / 1D
- $769.31+0.39%
State Street SPDR S&P 500 ETFSPY- Market value
- 2.47B
- Weight
- 0.30%
- AUM
- 817.87B USD
- Expense ratio
- 0.09%
- Price / 1D
- $765.72+0.41%
Vanguard Morningstar Value ETFVTV- Market value
- 1.75B
- Weight
- 0.68%
- AUM
- 256.5B USD
- Expense ratio
- 0.03%
- Price / 1D
- $226.4+0.54%
State Street Health Care Select Sector SPDR ETFXLV- Market value
- 1.43B
- Weight
- 3.20%
- AUM
- 44.76B USD
- Expense ratio
- 0.08%
- Price / 1D
- $174.62+1.29%
Vanguard Dividend Appreciation ETFVIG- Market value
- 1.04B
- Weight
- 0.79%
- AUM
- 130.9B USD
- Expense ratio
- 0.04%
- Price / 1D
- $243.91+0.69%
Continue in GoAI
Research ABTresearch.disclaimer











